Neutropenia · People with advanced non‐small cell lung cancer
Gefitinib leads to lower neutropenia compared with chemotherapy (high certainty).
1 finding from 1 review
Febrile neutropenia · People with advanced non‐small cell lung cancer
Gefitinib leads to lower febrile neutropenia compared with chemotherapy (high certainty).
1 finding from 1 review
Subgroup analysis:Incidence of parastomal hernia (open surgery) ( · individuals having a stoma formation
Prosthetic mesh placement probably leads to lower subgroup analysis:Incidence of parastomal hernia (open surgery) ( compared with standard treatment (moderate certainty).
1 finding from 1 review
Thrombocytopenia · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in thrombocytopenia compared with UFH prophylaxis (moderate certainty).
1 finding from 1 review
Thrombocytopenia · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in thrombocytopenia compared with fondaparinux prophylaxis (low certainty).
1 finding from 1 review
The incidence and severity of toxicities: leukopenia (WHO grade 3 to 4) · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion showed no clear difference in the incidence and severity of toxicities: leukopenia (WHO grade 3 to… compared with no treatment (low certainty).
1 finding from 1 review
The incidence and severity of toxicities: leukopenia (WHO grade 3 to 4) · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion + conventional treatment showed no clear difference in the incidence and severity of toxicities: leukopenia (WHO grade 3 to… compared with conventional medicine alone (low certainty).
1 finding from 1 review
Thrombocytopenia · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide showed no clear difference in adverse events: thrombocytopenia 12‐month compared with mycophenolate (low certainty).
1 finding from 1 review
Adverse effects: leukopenia · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide may leads to higher adverse events: leukopenia 12‐month compared with mycophenolate (low certainty).
1 finding from 1 review
Conversion to open surgery · adults undergoing inguinal and femoral hernia repair
1 finding from 1 review
Grade 1 ‐ 4 thrombocytopenia · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus mitomycin C changes grade 1 ‐ 4 thrombocytopenia compared with capecitabine plus mitomycin C (very low certainty).
1 finding from 1 review
Intervention not reported
Leukopenia** grade 3 or 4 (safety population) · women with metastatic breast cancer
The intervention probably leads to higher leukopenia** grade 3 or 4 (safety population) (moderate certainty).
1 finding from 1 review
Thrombocytopenia
Heparin prophylaxis showed no clear difference in thrombocytopenia compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Intervention not reported
Grade 3 to 4 neutropenia · people with metastatic colorectal cancer ‐ KRAS exon 2 MT
The intervention leads to lower grade 3 to 4 neutropenia (high certainty).
1 finding from 1 review
Intervention not reported
Grade 3 to 4 neutropenia · people with metastatic colorectal cancer ‐ extended RAS WT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Grade 3 to 4 neutropenia · people with metastatic colorectal cancer ‐ extended RAS MT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Grade 3 to 4 neutropenia · people with metastatic colorectal cancer, not selected by KRAS status
The intervention probably leads to lower grade 3 to 4 neutropenia (moderate certainty).
1 finding from 1 review
Intervention not reported
Grade 3 to 4 neutropenia · people with metastatic colorectal cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Grade 3 to 4 neutropenia · people with metastatic colorectal cancer, not selected by KRAS status
1 finding from 1 review
Intervention not reported
Grade 3 to 4 neutropenia · people with metastatic colorectal cancer, not selected by KRAS status
1 finding from 1 review